💸 The Tape

The psychedelic therapeutics sector just got its most significant clinical data readout to date — and it wasn't from psilocybin.

Definium Therapeutics announced positive topline results from Emerge, its first randomized, double-blind, placebo-controlled Phase 3 study evaluating a single dose of DT120 (lysergide) ODT 100 µg — an orally disintegrating tablet formulation of LSD — in adults with major depressive disorder (MDD). The trial met its primary endpoint with a level of statistical significance and clinical differentiation that, if confirmed in subsequent studies, could fundamentally reshape how depression is treated.

For an industry that has been waiting years for a psychedelic compound to deliver Phase 3 results strong enough to support an FDA filing, this is the moment that moves the conversation from theory to evidence.

The Numbers

The headline data is striking. Patients who received a single dose of DT120 showed a least squares mean change of -13.3 points on the MADRS (Montgomery-Åsberg Depression Rating Scale) at Week 6, compared to -5.2 for placebo — a placebo-adjusted difference of -8.1 points with a p-value of <0.0001.

To put that in context, existing FDA-approved antidepressants typically show placebo-adjusted MADRS improvements of 2-3 points in their registration trials. An 8.1-point separation from placebo — from a single dose — is in a different category entirely.

But the efficacy story goes beyond the primary endpoint. The effect was rapid: at Week 1, the placebo-adjusted MADRS reduction was -14.2 points (p<0.0001), meaning patients experienced the most dramatic improvement within the first seven days. And it was durable: at Week 12 — nearly three months after a single dose — the placebo-adjusted reduction was still -7.3 points (p<0.0001).

A single administration producing statistically significant improvement that persists for three months challenges the fundamental treatment paradigm in psychiatry, where patients typically take daily medications for months or years with dose adjustments, side effect management, and frequent treatment changes.

Response and Remission

The response and remission rates further illustrate the clinical differentiation. At Week 6, 35% of DT120 patients achieved a MADRS response (defined as a 50% or greater improvement from baseline), compared to just 7% on placebo — a 28-percentage-point separation. Remission — defined as a MADRS score of 12 or below, essentially meaning the patient no longer meets criteria for depression — was achieved by 24% of DT120 patients versus 3% on placebo.

These are meaningful numbers for a treatment-resistant population. The mean baseline MADRS score was approximately 34.5 across both groups, indicating moderate to severe depression at study entry. Achieving a 24% remission rate from a single dose in patients with that severity of illness — and maintaining it through Week 12 — represents a clinical outcome that few existing therapies can match.

CEO Rob Barrow called the results "unprecedented and highly differentiated," adding that they "could support a fundamentally new approach to treating MDD for patients and providers who continue to face the limitations of existing treatment options."

Safety and Tolerability

For any psychedelic therapeutic, the safety profile is as important as efficacy — and Emerge delivered reassuring data on that front.

99% of treatment-emergent adverse events were mild to moderate in severity, transient, and predominantly occurred on the day of dosing. No new safety signals were identified, and critically, there was no increase in suicidal ideation or behavior — a finding that addresses one of the most sensitive concerns regulators have with any novel antidepressant mechanism.

Discontinuation rates were low and comparable between treatment groups, suggesting that patients tolerated the experience well enough to remain in the study through completion.

The dosing day logistics are also commercially relevant. Patients were assessed hourly from hours 5 through 8 on a structured end-of-session checklist (EoSC). The average time to meeting discharge criteria was 5.8 hours, with a median of 5.1 hours and 100% of patients meeting criteria by hour 8. That's a manageable clinical session — comparable to the monitoring window for Spravato (esketamine), which is already administered in certified healthcare settings with a similar observation period.

What This Means for Psychedelic Therapeutics

Definium's Emerge results arrive at a moment when the psychedelic therapeutics sector desperately needed a Phase 3 win.

Compass Pathways' COMP360 psilocybin program has been advancing toward potential FDA approval, but the regulatory path for psilocybin remains complicated by the need for extended therapeutic support sessions, therapist training requirements, and REMS (Risk Evaluation and Mitigation Strategy) programs that could limit commercial scalability.

MDMA-assisted therapy for PTSD — previously the sector's most advanced program through Lykos Therapeutics — received an FDA Complete Response Letter in 2024, sending the program back for additional work and deflating expectations for the entire class.

AtaiBeckley's BPL-003 psilocybin program is in Phase 3 but hasn't reported pivotal results yet. Incannex's PSX-001 showed promise in Phase 2 for generalized anxiety but remains earlier stage.

Against that backdrop, DT120's Phase 3 results — with an 8.1-point placebo-adjusted MADRS improvement, 24% remission from a single dose, durability through 12 weeks, and a clean safety profile — represent the strongest clinical evidence package any psychedelic compound has produced in a registration-quality trial.

The orally disintegrating tablet formulation is also commercially significant. Unlike psilocybin programs that require extended therapy sessions lasting 6-8 hours with trained facilitators, or MDMA protocols requiring multiple preparation and integration sessions, DT120's delivery model — a single tablet with a 5-6 hour monitoring window and no required psychotherapy component — is designed for integration into existing clinical infrastructure. That's not just a scientific advantage; it's a reimbursement and scalability advantage.

The Regulatory Path Forward

Definium described Emerge as "the first of our Phase 3 studies to report results," indicating additional pivotal trials are either underway or planned. FDA typically requires two adequate and well-controlled studies for approval of a new drug application, though a single study with sufficiently robust results — particularly with the magnitude of effect seen here — could potentially support an accelerated pathway.

The April 2026 Trump Executive Order on psychedelic therapeutics — which prioritized accelerated FDA review, expanded patient access through Breakthrough Therapy and Right to Try pathways, and directed federal funding to match state investments in psychedelic research — creates a regulatory environment that is more favorable to novel psychiatric treatments than any in recent memory.

Whether Definium pursues Breakthrough Therapy Designation for DT120 — which would provide more intensive FDA guidance and potentially faster review — hasn't been disclosed, but the Emerge data would appear to support such a request based on the substantial improvement over existing therapies demonstrated in the trial.

The Bottom Line

Major depressive disorder affects an estimated 280 million people worldwide and remains one of the leading causes of disability globally. Existing treatments — SSRIs, SNRIs, atypical antidepressants, and even Spravato — work for some patients but leave millions undertreated, often requiring months of trial-and-error prescribing with significant side effect burdens.

A single-dose treatment that produces rapid, robust, and durable improvement in moderate-to-severe depression — with a manageable safety profile and a clinical delivery model that fits existing healthcare infrastructure — isn't incremental. It's the kind of result that, if replicated, changes how an entire disease is treated.

The psychedelic therapeutics sector has been long on promise and short on Phase 3 data. Definium just delivered the data. What happens next — additional trials, regulatory engagement, and ultimately an FDA submission — will determine whether DT120 becomes the first psychedelic-derived medicine approved for depression in the United States.

The Emerge results suggest the answer should be yes. The science just got a lot harder to ignore.

📈 Dog Walkers

$CURLD ( ▼ 4.14% ) Announces AGM Results

Curaleaf shareholders just cleared the runway for everything the company needs to do next — and they did it with overwhelming margins.

At the company's annual meeting on Friday, shareholders approved three critical resolutions that collectively position Curaleaf for its next chapter: redomiciliation to Delaware, removal of the automatic conversion feature on Multiple Voting Shares, and an option exchange program replacing underwater stock options with restricted share units.

The most significant vote was the plan of arrangement to continue the company out of British Columbia to Delaware — approved by 99.93% of votes cast. The Final Order Hearing is scheduled for June 25 at the Supreme Court of British Columbia, and if approved, the move gives Curaleaf a U.S. corporate domicile that aligns with exchange listing requirements and simplifies the governance structure for institutional investors.

The Proposed Amendment removing the automatic conversion of Multiple Voting Shares upon a major exchange listing passed with 97.01% overall support and 79.66% among minority shareholders (excluding Chairman Boris Jordan's holdings). This amendment preserves the dual-class share structure through an uplisting — a governance decision that keeps Jordan's voting control intact while the company pursues Nasdaq or NYSE access following its 1-for-3 reverse stock split completed earlier this month.

The Option Exchange Program — converting up to 10 million underwater options (exercise prices at or above $5.00) into RSUs — is expected to launch June 30. It's a practical cleanup that replaces worthless compensation instruments with equity that actually incentivizes employees.

All seven director nominees were re-elected with approval rates exceeding 97%, with Jordan receiving 97.36% support.

The sequence is now clear: Delaware redomiciliation, share structure cleanup, option exchange, and a company that has already executed its reverse stock split and is openly preparing for a major U.S. exchange listing. Every corporate governance prerequisite is falling into place.

🗞️ The News

📺 Trade To Black

The Stage Is Set For The Most Important Hearing In Cannabis History | TTB Presented by Flowhub

• ALJ Hearing Countdown: Michael Bronstein breaks down the scheduling and participation dynamics ahead of the June 29 DEA hearing, where only opponents — SAM, NDASA, state attorneys general, and others — have been designated to participate, while reform supporters like NORML and DPA were denied entry.

• Litigation vs. Hearing Collision: The consolidated D.C. Circuit lawsuit and pending stay motion from the same parties participating in the ALJ hearing create a critical question — could a court-issued stay freeze the rescheduling order and disrupt the hearing before testimony even begins?

• Industry Momentum: The conversation covers the accelerating pace of reform — Trulieve on the NYSE, Glass House's listing application, DEA on-site inspections, the Virginia budget compromise, and growing institutional re-engagement — all converging as the industry enters its most consequential week.

• Hemp & Federal Policy: Bronstein shares ATACH's read on the federal hemp THC ban outlook, where Congress actually stands, and what the organization is doing behind the scenes to defend cannabis reform as multiple policy threads — rescheduling, hemp regulation, and banking — converge simultaneously.